Kenvue (NYSE:KVUE - Get Free Report) had its price objective lowered by investment analysts at UBS Group from $24.00 to $23.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a "neutral" rating on the stock. UBS Group's price objective indicates a potential upside of 8.44% from the stock's current price.
Other equities research analysts have also issued research reports about the stock. Barclays raised shares of Kenvue to a "hold" rating in a research note on Thursday, December 12th. Citigroup reduced their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. Piper Sandler upgraded Kenvue from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $23.27.
Get Our Latest Research Report on KVUE
Kenvue Trading Up 1.7 %
Shares of Kenvue stock traded up $0.36 during trading on Thursday, reaching $21.21. 5,836,593 shares of the stock were exchanged, compared to its average volume of 8,815,551. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $40.66 billion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. Kenvue has a 1 year low of $17.67 and a 1 year high of $24.46. The stock's fifty day moving average is $22.50 and its 200 day moving average is $21.64.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period last year, the company earned $0.31 EPS. The business's quarterly revenue was down .4% compared to the same quarter last year. As a group, equities research analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Kenvue
Several institutional investors and hedge funds have recently made changes to their positions in the company. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Riverview Trust Co bought a new position in Kenvue during the 3rd quarter valued at about $30,000. Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue during the 3rd quarter valued at about $35,000. Fortitude Family Office LLC raised its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after purchasing an additional 1,441 shares during the period. Institutional investors own 97.64% of the company's stock.
About Kenvue
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
